Skip to main content
HealthPartners

Coverage criteria policies

Necitumumab (Portrazza®)

These services may or may not be covered by your HealthPartners plan. Please see your plan documents for your specific coverage information. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage.

Administrative Process

Necitumumab (Portrazza) requires prior authorization from HealthPartners Pharmacy Administration.

Coverage

Portrazza is generally covered subject to the indications listed below when all of the following criteria are met, and per member plan documents.

Initial Authorizations:

  1. Prescribed by or in consultation with an oncologist; and,
  2. Prescribed as first line treatment for patients diagnosed with metastatic squamous non-small cell lung cancer (NSCLC); and,
  3. When used in combination with gemcitabine and cisplatin; and,
  4. With documentation of a risk/benefit discussion and medical necessity statement for the addition of necitumumab; and,
  5. Portrazza is prescribed within the FDA-approved dosing regimen.

Initial approvals will be provided for six months.

Reauthorizations:

  1. Patient has been seen by provider within the past 12 months; and,
  2. Patient has been adherent to therapy; and,
  3. Patient has not had disease progression while on therapy; and,
  4. Portrazza is prescribed within the FDA-approved dosing regimen.

Reauthorizations will be provided for 12 months with documentation that the medication is effective.

Definitions

Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Limitation of Use: Portrazza is not indicated for treatment of non-squamous non-small cell lung cancer.

If available, codes are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all-inclusive.

HCPCS Code

Code

Description

J9295

Injection, necitumumab, 1mg

NDC Codes

Code

Description

00002771601

Portrazza 800 MG/50ML SOLN

CPT Copyright American Medical Association. All rights reserved.  CPT is a registered trademark of the American Medical Association.

Products

This information is for most, but not all, HealthPartners plans. Please read your plan documents to see if your plan has limits or will not cover some items. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage. These coverage criteria may not apply to Medicare Products if Medicare requires different coverage. For more information regarding Medicare coverage criteria or for a copy of a Medicare coverage policy, contact Member Services at 952-883-7979 or 1-800-233-9645.

References

  1. Portrazza prescribing information. Eli Lilly and Company, Indianapolis, IN. November 2015

Go to

Policy activity

  • 02/16/2016 - Date of origin
  • 04/01/2019 - Effective date
Review date
  • 02/2019
Revision date
  • 02/04/2019

Related content